Biogen Idec, Inc. (NASDAQ:BIIB)

CAPS Rating: 4 out of 5

The Company creates new standards of care in oncology, neurology, immunology and other specialty areas of unmet medical need and engaged in the development, manufacturing, and commercialization of novel therapies.

Results 1 - 20 of 97 : 1 2 3 4 5 Next »

Recs

0
Member Avatar racoveanul (80.17) Submitted: 7/11/2014 10:17:42 AM : Outperform Start Price: $318.14 BIIB Score: +5.61

I expect at least a point a week from this stock, for the next five years.

Recs

0
Member Avatar CramersSkeeDaddy (97.76) Submitted: 7/10/2014 2:27:26 PM : Outperform Start Price: $320.55 BIIB Score: +4.90

to the moon

Recs

0
Member Avatar Flygal5 (99.25) Submitted: 7/8/2014 6:47:19 PM : Outperform Start Price: $322.62 BIIB Score: +4.31

Cancer drugs and new MS drug

Recs

0
Member Avatar SnowBawl (< 20) Submitted: 5/15/2014 7:57:08 AM : Outperform Start Price: $295.63 BIIB Score: +9.66

4 Big Elderly. Reeves.

Recs

0
Member Avatar km00nster (< 20) Submitted: 5/8/2014 7:59:02 PM : Outperform Start Price: $320.20 BIIB Score: -0.30

BIIB and GILD are my 2 top holdings. In the long term, this is a no brainer. Very stacked pipeline.

Recs

0
Member Avatar yooperking (63.10) Submitted: 4/2/2014 10:50:16 AM : Outperform Start Price: $312.75 BIIB Score: +3.37

PEG ratio of 1.5, Quarterly revenue growth (yoy) or 38.6% and Quarterly earnings growth (yoy) of 56.5% makes this company's stock a good buy. Institutional ownership of 94.5%, 0.9% insider ownership and a 1.9 short ratio leaves room for more buyers.

Recs

0
Member Avatar TerryFool (20.72) Submitted: 3/10/2014 8:31:23 PM : Outperform Start Price: $297.84 BIIB Score: +6.09

EPS 1YR 25% 2YR 20% 5YR 18%

Recs

0
Member Avatar RideWildfire (56.84) Submitted: 2/11/2014 11:07:00 AM : Outperform Start Price: $315.77 BIIB Score: -2.35

They are delivering relief to a large population in ways that lead their competitors.

Recs

0
Member Avatar TerryHoodSr (60.36) Submitted: 7/21/2013 1:30:37 AM : Outperform Start Price: $289.85 BIIB Score: +11.44

growth

Recs

0
Member Avatar KimLanners (< 20) Submitted: 6/12/2013 9:18:59 AM : Underperform Start Price: $311.64 BIIB Score: -3.60

Margins are high and up, but once they go down, the valuation should sink dramatacally. I dont see much room

Recs

1
Member Avatar sugarmag23 (< 20) Submitted: 6/5/2013 11:47:30 AM : Outperform Start Price: $215.34 BIIB Score: +35.59

this company will keep coming up with a succession of innovative drugs to treat deadly diseases.

Recs

1
Member Avatar bear713 (< 20) Submitted: 5/22/2013 11:18:31 AM : Outperform Start Price: $236.36 BIIB Score: +25.81

This pharmaceutical company has a well defined niche market and a proven track record of inovation.

Recs

1
Member Avatar elv1659 (46.33) Submitted: 4/9/2013 12:24:42 PM : Outperform Start Price: $192.92 BIIB Score: +49.69

Have a new pill for MS. Before patients had to take infusions. Much easier to administer and control disease.

Recs

1
Member Avatar Phuman2 (< 20) Submitted: 4/9/2013 8:54:25 AM : Outperform Start Price: $194.51 BIIB Score: +48.11

Steady growth and high profit margins

Recs

0
Member Avatar FutureMonkey (82.70) Submitted: 3/2/2013 2:57:41 PM : Outperform Start Price: $167.64 BIIB Score: +72.37

Top 25 pick

Recs

0
Member Avatar 42asdf (44.21) Submitted: 3/1/2013 4:50:40 PM : Outperform Start Price: $167.64 BIIB Score: +72.37

has great growth, profit margins, and financial health. While it's p/e is fairly high (28.9), it is lower than the industry average (45.2).

Recs

0
Member Avatar NHWeston102 (76.69) Submitted: 2/7/2013 11:47:24 AM : Outperform Start Price: $159.11 BIIB Score: +81.85

If you can't develop a ground-breaker, buy one!! Tysabri will do BIIB good!

Recs

0
Member Avatar JorgeAura (23.06) Submitted: 2/2/2013 4:57:02 PM : Underperform Start Price: $156.15 BIIB Score: -86.16

Nasdaq in maximums.

Recs

2
Member Avatar TMFHelical (98.71) Submitted: 11/13/2012 9:54:12 AM : Outperform Start Price: $139.82 BIIB Score: +100.34

One of the leaders of an annual industry audit that looks at value creation in the biotech space.

http://caps.fool.com/Blogs/a-look-at-established-biotech/774287

Recs

1
Member Avatar macginty (< 20) Submitted: 7/30/2011 1:07:51 PM : Outperform Start Price: $105.91 BIIB Score: +170.50

I feel that Tysabri's proven track-record over the past five years, as a prime treatment for multiple sclerosis, is providing real and worthwhile results for a very significant number of people, who must live with this otherwise 'incurable' disease.

Results 1 - 20 of 97 : 1 2 3 4 5 Next »

Featured Broker Partners


Advertisement